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determine the effect of enteric coating on
enzyme treatment for canine exocrine pancreatic
efficiency
Aran Mas1†, Peter-John M Noble1†, Peter J Cripps1, Daniel J Batchelor1, Peter Graham2 and Alexander J German1*Abstract
Background: Enzyme treatment is the mainstay for management of exocrine pancreatic insufficiency (EPI) in dogs.
‘Enteric-coated’ preparations have been developed to protect the enzyme from degradation in the stomach, but
their efficacy has not been critically evaluated. The hypothesis of the current study was that enteric coating would
have no effect on the efficacy of pancreatic enzyme treatment for dogs with EPI.
Thirty-eight client-owned dogs with naturally occurring EPI were included in this multicentre, blinded, randomised
controlled trial. Dogs received either an enteric-coated enzyme preparation (test treatment) or an identical
preparation without the enteric coating (control treatment) over a period of 56 days.
Results: There were no significant differences in either signalment or cobalamin status (where cobalamin deficient
or not) between the dogs on the test and control treatments. Body weight and body condition score increased in
both groups during the trial (P<0.001) but the magnitude of increase was greater for the test treatment compared
with the control treatment (P<0.001). By day 56, mean body weight increase was 17% (95% confidence interval
11-23%) in the test treatment group and 9% (95% confidence interval 4-15%) in the control treatment group. The
dose of enzyme required increased over time (P<0.001) but there was no significant difference between treatments
at any time point (P=0.225). Clinical disease severity score decreased over time for both groups (P=0.011) and no
difference was noted between groups (P=0.869). No significant adverse effects were reported, for either treatment,
for the duration of the trial.
Conclusions: Enteric coating a pancreatic enzyme treatment improves response in canine EPI.
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Exocrine pancreatic insufficiency (EPI) is a common
condition in dogs, resulting from inadequate functional
reserve of pancreatic acinar tissue [1]. The most com-
mon cause of EPI is pancreatic acinar atrophy, although
other causes have been reported, including chronic pan-
creatitis, pancreatic neoplasia and (possibly) congenital
hypoplasia. Clinical signs only develop when a critical* Correspondence: ajgerman@liverpool.ac.uk
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reproduction in any medium, provided the ormass (e.g. >90%) of exocrine tissue has been lost, and
result from maldigestion and subsequent malabsorption.
Clinical management usually involves enzyme replace-
ment therapy with the addition of dietary modification
(e.g. highly digestible diet) and ancillary therapies (e.g.
antibacterials) if response to enzyme alone is poor [1].
Most dried pancreatic extracts are given as a powdered
formulation, although ‘enteric-coated’ preparations have
been developed in which granules of enzyme powder are
coated in a lacquer that protects the enzymes from deg-
radation in the stomach. However, whilst widely used,
the effectiveness of enteric-coated preparation has been
questioned, and one study found that such formulations. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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contrast, a more recent study found no difference in re-
sponse or long term survival between those dogs taking
uncoated and coated preparations [3]. All studies to date
have suffered from the limitation that they are retro-
spective and uncontrolled. Thus, the true effect that en-
teric coating has on efficacy remains unclear. As a
result, there is a need to determine whether a difference
in efficacy exists between types of enzyme supplementa-
tion used for the treatment of canine EPI. Given the
conflicting information from previous studies, our
chosen hypothesis was that enteric coating of a pancre-
atic enzyme extract would have no effect on the efficacy
of treatment for canine EPI. Our aim was to conduct the
first blinded randomised controlled trial (RCT) assessing
therapeutic efficacy in this condition.Methods
Trial design and objectives
The study was a multicentre randomised blinded ‘posi-
tive controlled’ trial, and used a two-group parallel de-
sign. The main objective was to determine the effect of
enteric coating on efficacy of a pancreatic enzyme sup-
plement in the treatment of canine EPI. The studied
complied with the University of Liverpool Guidelines on
Animal Welfare and Experimentation, and was approved
by the University of Liverpool Research Ethics Commit-
tee (RETH000328). Prior to enrolment, owners were
informed as to the nature of the study and gave their
informed consent in writing. At the end of the trial, all
owners were asked to complete a trial feedback form to
ensure that they were happy with trial conduct. As far as
possible (for a trial in a veterinary species), the studied
complied with the principles of Good Clinical Practice
(GCP) [4].Study subjects
Cases were recruited between March 2009 and July
2011, when the target for enrolment had been reached.
Dogs recently (within two weeks) diagnosed with EPI
(i.e. serum trypsin-like immunoreactivity [TLI] less than
the lower limit of the respective laboratory reference
interval, typically 2.0-3.0 μg/L) were eligible for enrol-
ment. Other eligibility criteria included absence of any
concurrent disease that might affect diagnosis, response
to treatment (especially body weight gain) or prognosis
including concurrent cardiac disease, renal disease, hep-
atic disease, endocrine disease or neoplasia. Further, it
was a requirement that routine haematological and
serum biochemical analysis had been performed within
4 weeks of enrolment. Finally, cases could not have
previously been treated with pancreatic enzyme
supplementation.Any first-opinion veterinary practice with a case fitting
the inclusion criteria was eligible to request enrolment
in the trial. When a request was made, one of the study
observers (AM, PJN, AJG) discussed the study outline
with the primary care veterinarian, who in turn dis-
cussed the trial with the owner of the eligible dog. As-
suming that the practice remained interested, the owner
and primary care veterinarian could decide whether or
not the trial visits were conducted at the Small Animal
Teaching Hospital (SATH), or at the practice of their
primary care veterinarian. If owners and/or veterinarians
preferred the latter, a detailed study pack was then
posted (by next-day recorded delivery). This pack con-
tained a detailed information brochure for the veterinar-
ian, explaining their duties as a trial investigator, an
owner information sheet, a consent form, a form to rec-
ord details of all visits and client communication, and a
9-point body condition score (BCS) chart [5]. In
addition, the specific therapy, for the whole of the trial,
was also provided (see below). For cases that were en-
rolled at the SATH, the owner information sheet and
consent form were posted to the client prior to the first
appointment.
Trial publicity and incentives
In order to maximise recruitment, the trial was adver-
tised in a number of ways, including mailshots to local
veterinary practices, advertising footnotes to referral let-
ters (written by all clinicians within the SATH for the
duration of the trial), letters submitted to the veterinary
press (e.g. Veterinary Record), advertising by the trial
sponsor when their company representatives visited first
opinion practices, and sponsored continuing education
meetings organised for first-opinion veterinarians. In
addition, a footnote advertising the trial was added to
the results report for any TLI test result diagnostic for
EPI at a large commercial clinical pathology laboratory
(NationWide Laboratories, Poulton-le-Fylde, UK). In all
cases, veterinarians with potentially eligible cases were
encouraged to contact the study observers for details.
For cases where the owner wished to attend the SATH
for their appointments, the costs of travel were reim-
bursed. In addition, the study medication was provided
free of charge. Finally, to encourage compliance, any
costs for the contributing primary veterinarians were
defrayed by a payment of £300 for every case that com-
pleted the trial where all study paperwork was returned
in a timely manner. Study observers did not receive any
incentives or remuneration for completing the trial.
Roles and responsibilities
For cases seen at the SATH, the study observers (AM,
PJN, AJG) were responsible for liaising with the owners,
performing the examination at each visit and modifying
Table 1 The clinical signs scoring system used two assess
efficacy of two enzyme treatments for canine exocrine
pancreatic insufficiency
Criterion Description Score
















Fecal consistency Normal 0











Clinical signs of dogs with EPI were assessed at each study visit. All clinical
signs listed above were assigned a score from 0 to 3, as in the table. Individual
clinical signs scores were then added together to generate a global score, with
a minimum of 0 (no signs) and a maximum of 24 (severe signs).
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veterinarian was informed of case progress throughout
by letter. In the cases not referred to SATH, the primary
care veterinarian was responsible for examining and
managing the dog, for liaising with the client, and for
completing study paperwork. However, they could con-
tact the study observers at any time if they had questions
regarding case management.
Treatments
Both the test treatment and control treatment were
based upon a commercially-available porcine pancreatic
enzyme extract with an enteric coating, designed to pro-
tect the active enzyme from acid digestion and ensure
high concentrations reach the small intestine (Lypex,
Vet Plus Ltd., Lytham, UK; 30,000 ph Eur U lipase,
18750 ph Eur U amylase, 1200 ph Eur U protease per
capsule). This product is based on Pancreatin, a highly
active, porcine-derived enzyme combination. After active
ingredient extraction, the dried enzyme is then pelleted
and contains no excipient. An enteric coating is then ap-
plied, which is added in a solvent-free polymethacrylic
acid/ester process using a dispersion film former. The
coated pellets range from 1.4-2.4 mm in size. The prod-
uct was manufactured by Nordmark Arzneimittel GmbH
& Co. KG (Uetersen, Germany), on behalf of VetPlus
Ltd.
The test treatment was identical to the commercially
available product; the control treatment was similar in
all aspects, except that it lacked the enteric coating, and
was not commercially available. However, the organolep-
tic properties were identical and both treatments were
presented in similar plain packaging (see below), ensur-
ing that test and control treatment could not be distin-
guished. Nordmark Arzneimittel purpose-formulated
both treatments for the trial on 24/11/08, with an expiry
date of 30/11/11. Efficacy was tested and confirmed and
the product was certified to be free from microbial con-
tamination. Sufficient treatment was manufactured for a
total of 40 dogs (with 20 receiving the test treatment,
and 20 receiving the control product) and, in order to
budget for difference in dogs size, enough product was
manufactured to last 2 months even for a large dog
where dose increases were required at each visit (see
below).
The same starting dose of enzyme was used for both
treatments: one capsule per day was administered to
dogs <10 kg, divided over two meals, whilst 2 capsules/
day (1 capsule per meal) was given to dogs >10 kg. Dur-
ing administration, the gelatin capsule was opened and
the product mixed well with the food immediately prior
to feeding. In order to avoid the risk of any skin irrita-
tion, owners were instructed to wear gloves when hand-
ling the capsules.Initial assessment and enrolment
During the initial assessment, a detailed medical history
was taken, physical examination performed, body weight
was measured, and body condition was scored [5]. Infor-
mation about the severity of clinical signs was then
obtained from the owner, using a standardised system
(Table 1). This enabled each clinical sign (i.e. appetite,
frequency of defecation, faecal consistency, vomiting,
flatulence, borborygmus, coprophagia and attitude/activ-
ity), to be scored semi-quantitatively, in a manner simi-
lar to another clinical scoring system used for chronic
enteropathy [6].
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cussed with the owner and, assuming that they were
happy, they were asked to sign the study consent form.
Thereafter, dogs were allocated a study number and the
treatment dispensed. The owners were instructed on
how to use the treatment and any specific questions that
the owner had were answered at this stage.Monitoring, treatment alterations and follow-up
A summary of the study protocol is given in Figure 1.
Throughout the trial, dogs returned on a weekly basis
for administration of subcutaneous cobalamin (see
below). Detailed assessments were conducted on days
14, 28 and 56. At each visit, a physical examination was
performed, body weight was measured (using the same
electronic scales as for the first visit), and a body condi-
tion score was performed. In addition, clinical signs were
again scored using the same questionnaire as for the ini-
tial visit. Compliance with administration of the treat-
ment was confirmed and, if necessary, dosage alterations
were made and additional therapy was added.
In addition to the official re-evaluation visits, clients
contacted either the attending veterinarian or study
observers using telephone calls and, occasionally, e-mail
updates.Figure 1 Summary of the trial design and inclusion of dogs. Forty dog
one of two enzyme treatments (test e.g. coated and control e.g. uncoated)
56). Information in the lower part of the figure refers to the procedures con
up. Arrows indicate when doses of parenteral cobalamin were injected. Oth
remaining within the trial at the respective points.Treatment alterations, use of additional therapy, and diet
The intention was that only the enzyme supplement and
weekly cobalamin injections (see below) would be admi-
nistered during the trial. However, in accordance with
normal clinical practice, alterations in enzyme dose and
the addition of other therapies were allowed if response
to therapy was poor. Primary care veterinarians made all
treatment changes, after discussing them with one of the
study observers, and in accordance with a standardised
protocol. In this regard if, at the first reassessment
(14 days), clinical response was deemed to be insufficient
(e.g. poor weight gain, lack of resolution of clinical
signs), the dose of enzyme was doubled. A further en-
zyme dosage increases were allowed on days 28 and 56,
if necessary.
Given that hypocobalaminaemia is a negative prognos-
tic indicator in canine EPI [3], and in order to ensure that
this was not a confounding factor during the trial, weekly
subcutaneous injections of cobalamin (at 20 μg/kg) were
administered to all dogs. This treatment was given irre-
spective of whether hypocobalaminaemia was present in
pre-trial serum biochemical results. No other treatment
was initially allowed in any of the dogs. Additional ther-
apies were avoided as far as possible but if, in the opinion
of the attending veterinarian they were deemed to be ne-
cessary, then they could be added from third visit (weeks, with exocrine pancreatic insufficiency, were randomised to receive
, and were re-examined at 3 follow-up visits (day 14, day 28 and day
ducted at each visit. BCS: body condition score; LTFU: lost to follow
er than the timeline, all numbers refer to dogs recruited and
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vers. Sanctioned additional therapies included the use of
either antibacterials (e.g. oxytetracycline at 10 mg/kg
q8 h PO, or metronidazole at 10 mg/kg q12 h PO) or
histamine-2-receptor antagonists (e.g. ranitidine at 2 mg/
kg q12h PO).
In order to avoid any potential cofounding effect of a
diet change on treatment response, all owners were
instructed to continuing feeding their dog’s existing diet
at the same level. In all cases, dogs were fed twice daily.
Details of exact diets fed were not recorded.
Patient welfare, adverse events, early trial
discontinuation, and euthanasia
Throughout the study, all efforts were made to safeguard
the welfare of the dogs enrolled, and owners were free to
withdraw at any stage. The attending veterinarian
recorded details of all welfare matters, including proto-
col deviations, suspected adverse events, development of
concurrent medical problems and euthanasia. In
addition, they informed the study observers immediately
to agree an appropriate course of action. If withdrawal
from the trial proved to be necessary, the study obser-
vers recorded the reasons.
For adverse events where the treatment was suspected
to be the cause, participation in the study was to be sus-
pended immediately. Where it was thought to be un-
likely that an adverse event was related to the treatment,
the dog was allowed to continue with the trial, provided
that the owners agreed. Participation could also be sus-
pended if an enrolled dog developed an unrelated condi-
tion, whilst enrolled in the trial.
Where it became necessary to perform euthanasia (e.g.
poor response to therapy, development of another med-
ical disorder), the attending veterinary surgeon would
perform this (using overdose of intravenous sodium
pentobarbital), after obtaining written consent from the
owner.
Randomisation procedures
Sequence generation and allocation concealment
The 40 treatments (20 test and 20 control) were
assigned a study number from 1 to 40, based upon a
randomised sequence generated in Minitab (Minitab Inc,
State College, PA, USA) by the trial statistician (PJC).
Treatments were given in sequence according to ascend-
ing study number, and each group of four study num-
bers contained two of each treatment. This was to
ensure that numbers remained approximately even
throughout the course of the study in case, for whatever
reason, it was not possible to recruit all cases. The trial
statistician sent the numbered sequence to the treatment
manufacturer, who assigned the respective treatments to
numbered packaging before posting to the studyobservers. The treatments were stored away from light
and at room temperature, until assigned. The study
observers were responsible for allocating dogs to their
respective treatment, which occurred in a sequential
fashion every time that a new case was enrolled. Neither
the study observers nor of any of the attending clinicians
were aware of the sequence of treatments.
Blinding
A two-stage blinding process was used; the first level
ensured that, for the duration of the trial, all owners,
attending veterinarians, and study observers were
blinded as to what treatment any of the dogs were on.
Identical packaging was used for all treatments, consist-
ing of plain plastic pots containing the treatment itself,
within plain outer cardboard. The only identifying mark
was the study number. As mentioned above, the treat-
ments themselves were identical, comprising granules
contained within unmarked gelatin capsules, and or-
ganoleptic properties were identical, both before and
after the gelatin capsules were opened.
Once all cases had been enrolled, and all dogs had
completed the study, the second stage of blinding was
then implemented. For this, the trial statistician passed
the randomisation sequence to a separate investigator
(DB) who was not involved in any other aspect of the
trial. This investigator broke the code, randomly
assigned a secondary study number to each dog, and
assigned the dogs to two groups, named “A” and “B”. A
coded spreadsheet of the trial data was then given to the
trial statistician, who performed all statistical analyses
without knowing which treatment was which. Only
when all statistical analyses had been completed were
the treatment identities revealed.
Outcome measures
The primary outcome measure of interest was change in
body weight. Secondary outcomes of interest included,
change in severity of clinical signs, change in BCS, the
dose of treatment used for each dog, and requirement
for additional medications. For clinical signs, a compos-
ite score was created, by adding together the results of
all clinical signs recorded in the questionnaire. All of
these outcome measures were decided prior to com-
mencement of the trial.
Sample size
At the conceptualization stage of the study, the trial sta-
tistician (PJC) performed a sample size calculation using
a statistical software package (Minitab). The primary
outcome measure (percentage gain in body weight) was
used and, based upon previous studies [7], the expected
mean (± standard deviation) change in body weight was
24 ±15.2%. A 1:1 test:control recruitment rate was
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been conducted in canine EPI, a clinically relevant differ-
ence in efficacy between treatments of 40% was decided.
This figure was based upon the opinions of the study
investigators. Calculations assumed that a power of 90%
was required to identify this difference with a two-sided
P of <0.05. Based upon these criteria, it was determined
that 20 animals per group would be required.
Data handling and statistics
Data were entered into an Excel spreadsheet (Microsoft
inc.) and checked for errors. Statistical analysis used
Minitab 16, STATA12 (Statacorp, College Station, TX,
USA), and Stats Direct version 2.6.2 (Stats Direct Ltd.,
Altrincham, UK). Standard descriptive statistics were
used to report baseline data (either median and range,
or mean ± standard deviation). Baseline data compari-
sons were made with Fisher’s exact test (for proportions)
or the Mann-Whitney test (for continuous variables).
The level of statistical significance was set at P<0.05 for
2-sided analyses. Outcome data were analysed both on
an intention to treat and per-protocol basis; where there
was a discrepancy in results, the former were considered
most important. In order to account for missing data in
the intention to treat analyses, imputation was per-
formed using the method of “Last Observation Carried-
Forward”.
For the primary outcome measure, namely body-
weight, the study design involved repeated measure-
ments of the same animal, and the effect of treatment
on weight was, therefore, investigated using a mixed-
effects linear regression model in STATA. The xtmixed
command was used, animal identity was declared as a
random effect and estimation was by Maximum Likeli-
hood. The effect of treatment was assessed using a mul-
tivariable model, which included treatment group, the
visit number and their interaction. Serum cobalamin
concentrations were included in the form hypocobalami-
naemic and normocobalaminaemic when results were
less than and greater than the lower limit of the refer-
ence range, respectively. The statistical significance of
variables in the model was examined using their Wald
statistic or their effect on the deviance.
Enzyme dose and BCS data did not meet the require-
ments needed for parametric analysis, and were analysed
with the signed ranks test (for time differences) and the
Mann-Whitney test (for differences between groups at
each time-point).
Protocol changes
A number of required changes were made to study
protocol at various stages, mainly because the rate of re-
cruitment of cases was slower than expected. Firstly, the
original plan was for all cases to be seen at the SATH;however, initial recruitment was slow and the major hur-
dle was found to be reluctance to travel. For this reason,
compensation for client travel was introduced and ad-
ministration by the first-opinion veterinarian was then
allowed. Second, as based upon the power calculation,
the initial intention was to recruit a total of 40 dogs (20
treatment and 20 controls). However, the slow recruit-
ment meant that there were concerns that the treat-
ments would exceed their expiry date, initial set for two
years after product manufacture. As a result, two treat-
ments were sacrificed (1 treatment, 1 control) and sent
back to the manufacturer so that enzyme activity and
microbial contamination could be retested, and enabling
an extension to the expiry date to be granted. The first
product was one from a dog that had been enrolled, only
to withdraw soon after starting (Figure 1). In order to
maintain blinding, the trial statistician randomly selected
the second product from the remaining treatments, by
choosing a treatment opposite to the first sacrificed
product.
Results
Study centres and dogs
A total of 5 dogs were enrolled at the SATH (control
treatment 3, test treatment 2), one practice enrolled 2
dogs (both test treatment), and the remaining 31 prac-
tices enrolled 1 dog each. These practices were widely
distributed across mainland United Kingdom.
Full details of the timeline of the trial, including with-
drawals, are given in Figure 1. Twenty dogs were initially
enrolled to the control treatment (uncoated enzyme). Of
these dogs, two were withdrawn (and euthanased) within
the first 14 days of the trial, one because of a poor re-
sponse and the other for an unrelated problem (aggres-
sion). The enzyme supplied for one of these dogs was
ultimately used to confirm product efficacy. A further
dog was withdrawn (and euthanased) between days 14
and 28 for a perceived poor response to therapy so that,
ultimately, 17 dogs completed the trial. For the test
treatment, one enzyme batch was used to confirm prod-
uct efficacy, meaning that 19 were dogs were enrolled in
this group. Of these dogs, one was lost to follow up be-
tween days 28 and 56, so that, ultimately, 18 completed
the trial.
The baseline characteristics of the two groups are
shown in Table 2. No significant group differences for
any of the starting characteristics were identified.
Primary outcome measure
Median (range) body weight for both groups is shown in
Table 3, and no significant group difference was identi-
fied (P=0.159). Body weight increased progressively in
both groups during the trial (P<0.001), and a significant
time-group interaction was evident whereby the
Table 2 Baseline characteristics of dogs on two different enzyme treatments for canine exocrine pancreatic
insufficiency
Criterion Test treatment (coated) Control treatment (uncoated) P value
Breed Border collie (1), CKCS (1), Akita (2), CKCS (1), —
Cocker spaniel (1), Dogues de Bordeaux (1),
GSD (12), Lhasa apso (1), mixed breed (2) GSD (13), mixed breed (2)
West Highland white terrier (1) Tibetan terrier (1)
Sex Male (8) Male (5) 0.329
Neutered male (4) Neutered male (3)
Female (2) Female (7)
Neutered female (5) Neutered female (5)
Age (months) 41 (12 to 108) 48 (11 to 144) 0.829
Cobalamin1 Hypocobalaminemic (5), normocobalaminemic (9), Hypocobalaminemic (7), normocobalaminemic (9), 0.668
Not measured (6) Not measured (4)
The table reports signalment and cobalamin status in dogs, with exocrine pancreatic insufficiency, randomised to receive one of two enzyme treatments (test e.g.
coated and control e.g. uncoated). Numerical data are expressed as median (range). CKCS: Cavalier King Charles Spaniel; GSD: German Shepherd Dog. 1Given that
various laboratories were used (with different reference ranges), cobalamin data expressed in categories (e.g. normcobalaminaemia, hypocobalaminaemia) rather
than as absolute concentrations. There were no differences between groups for any of the baseline parameters.
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than for the control treatment (P<0.001; Figure 2). In
this respect, by day 56, mean body weight increase was
17% (95% confidence interval 11-23%) in the test treat-
ment group, and increased by a mean of 9% (95% confi-
dence interval 4-15%) in the control treatment group.
These findings were similar whether data were assessed
on an intention-to-treat (using imputation) or a per-
protocol basis (data not shown).Secondary outcome measures
The results of all secondary outcome measures, at each
visit, are shown in Table 3. As with body weight, BCS
increased over time (P<0.001 at 56 days). Again, how-
ever, there was a group difference, with the BCS of the
dogs in the test treatment group increasing more than
those in the control treatment group (P=0.032 at
56 days). The dose of enzyme used, also increased with
time (P<0.001 at 56 days), but there was no significant
group difference at any time point (P=0.225 at day 56).
Further, whilst clinical disease severity score decreased
significantly over the trial (P=0.011 at 56 days), no differ-
ence was noted between treatment groups (P=0.869 at
day 56).Ancillary analyses
Given the number of hypocobalaminaemic dogs identi-
fied, the group comparison for the primary outcome
measure was reassessed, including presence of hypoco-
balaminaemia as a covariate. The presence of hypocoba-
laminaemia had a negative effect on weight gain
(P=0.027). Inclusion of Cobalamin status in the statis-
tical model, of change in body weight, resulted in slightlylarger coefficients for the time-group interaction but did
not alter the results and conclusions (data not shown).
Adverse effects
No significant adverse effects were reported, for either
treatment, for the duration of the trial.
Discussion
This study is the first blinded RCT assessing efficacy of
pancreatic enzyme therapy for canine EPI, and has been
reported in line with the ‘Reporting Guidelines for Ran-
domized Control Trials’ (REFLECT) statement [8]. The
principles of evidence-based medicine are now widely
accepted in veterinary medicine and, as a result, there is
an increasing need to generate objective data to guide
clinical decision-making. The findings of this study rep-
resent a considerable advance on the prior state of
knowledge regarding EPI therapy, which relied on retro-
spective case series to guide therapy. One such study
suggested that enteric-coated products were less effect-
ive than uncoated enzyme powders [2], although more
recent work suggested that there was no difference in re-
sponse to therapy between dogs on coated and uncoated
products [3]. Whilst these historical results should not
be overlooked completely, their findings should be inter-
preted cautiously, and greater weight given to findings
from prospective controlled trials such as the current
study.
Based upon the results reported, the study hypothesis
that enteric coating of a pancreatic enzyme extract would
have no effect on the efficacy of treatment for canine EPI,
should be rejected. Not only does this support the use of
enteric coated products for treatment of canine EPI, but it
emphasises the need to look beyond clinical signs (such as
Table 3 Outcome variables in dogs on two different enzyme treatments for canine exocrine pancreatic insufficiency
Criterion Treatment group P value
Test (coated) Control (uncoated) Time Time-group
Body weight (kg)
Before 21 ±8.8 (4 to 36) 26 ±10.3 (6 to 48) — 0.159
14 days 23 ±9.3 (5 to 40) 26 ±10.1 (7 to 48) 0.962 0.012
28 days 24 ±9.6 (5 to 39) 27 ±10.6 (8 to 48) 0.145 0.004
56 days 25 ±10.0 (6 to 39) 28 ± 10.6 (8 to 48) <0.001 <0.001
Body condition score1
Before 2 (1 to 5) 2 (1 to 6) — 0.233
14 days 3 (1 to 5) 2 (1 to 6) 0.018 0.800
28 days 3 (1 to 5) 2 (1 to 6) <0.001 0.593
56 days 4 (2 to 5) 3 (1 to 6) <0.001 0.032
Dose of enzyme2
Before 2 (1 to 2) 2 (1 to 4) — 0.669
14 days 2 (1 to 4) 2 (1 to 7) 0.075 0.311
28 days 2 (1 to 4) 2 (1 to 7) 0.002 0.722
56 days 2 (1 to 4) 4 (1 to 6) <0.001 0.225
Clinical score3
Before 11 (4 to 19) 13 (2 to 16) — 0.993
14 days 8 (2 to 12) 7 (2 to 15) 0.003 0.337
28 days 7 (1 to 13) 5 (0 to 11) 0.008 0.476
56 days 7 (1 to 13) 5 (0 to 11) 0.011 0.869
Other therapy
Before Oxytetracycline (1) Cimetidine (1) — —
14 days Oxytetracycline (2) Oxytetracycline (1) — —
28 days Oxytetracycline (2) Cimetidine (1) Metronidazole (1) Oxytetracycline (2) — —
56 days Oxytetracycline (1) Oxytetracycline (3) Ranitidine (1) — —
Dogs, with exocrine pancreatic insufficiency, were randomised to receive one of two enzyme treatments (test [e.g. coated] and control [e.g. uncoated]). Numerical
data are expressed as median (range), except for body weight, which is expressed as mean ± standard deviation (range). 1Body condition score assessed using
the 9-point system [5]. 2 Dose of enzyme in number of capsules per day. 3Clinical score was a composite score for a range of clinical signs, as described in Table 3.
Body weight increased progressively in dogs on both treatments (P<0.001), but a significant time-group interaction was evident with the magnitude of increase
being greater for the test treatment (coated enzyme) than for the control treatment (uncoated enzyme; P<0.001). BCS increased over time in both groups
(P<0.001), but increased more in the test treatment group (P=0.032 at 56 days). The dose of enzyme used increased (P<0.001 at 56 days) and whilst clinical
disease severity score decreased (P=0.011 at 56 days) over time, but with no significant treatment group differences noted.
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measurement of body weight, using the same set of cali-
brated electronic weigh scales is a precise means of con-
firming health, even though it is underused in primary
care companion animal practice [9].
Detailed steps were taken to ensure that the order of
treatment allocation was concealed from all study inves-
tigators and attending veterinarians. In the opinions of
the authors, the process of consecutively numbering
treatment, according to the predetermined allocation se-
quence, is superior to other possible approaches e.g.
colour-coding the test and control treatments, or label-
ling products with group identifier (e.g. A or B). Blinding
was further maintained by the use of identical packaging
and product, so that the products were impossible toidentify. A further safety measure came from the fact
that the study was small and most cases came from sep-
arate practices. As a result, in the unlikely event that an
investigator guessed the treatment allocation, this would
not be likely to have a major impact on the results of the
trial. Finally, in order to ensure that the statistician was
also blinded to treatment arms when analysing study
data, an additional level of blinding was added subse-
quent to trial completion. This ensured that, although
the subjects comprising each group were known, neither
the main study investigators nor the statistician himself
could influence the method of analysis. The authors be-
lieve that the procedures taken were extremely robust,
and suggest that such approaches be considered for
companion animal RCTs in the future.
Figure 2 Effect of pancreatic enzyme replacement on weight gain. Box and whisker plots illustrating the percentage change in body weight
in 40 dogs, with exocrine pancreatic insufficiency, randomised to receive pancreatic enzyme treatment either with or without an enteric coating.
The boxes depict median (horizontal line) and inter-quartile range (top and bottom of box), the whiskers show the 10-90% range, and outliers are
shown as separate points. Weight gain was significantly greater in the dogs treated with the coated preparation (P<0.01).
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when interpreting findings. Firstly, group sizes were
small, and study withdrawals reduced further the ability
to make comparisons. In addition to this, trial recruit-
ment was slower than expected, requiring changes in the
recruitment protocol (e.g. multi-centre vs. single-centre
recruitment) and the sacrifice of two batches of therapy
(one test and one treatment) to verify that enzyme activ-
ity was maintained. Despite these problems, differences
were identified for the primary outcome measure, sug-
gesting that the study power had been sufficient. That
said, the use of larger group sizes might have enabled
subtle differences in the secondary outcome measures to
be identified. The switch from single-centre to multi-
centre design was an added complication, and meant
that 5 cases were recruited from one centre, with inher-
ent concerns of introducing unwanted influence or pos-
sible bias. However, since these 5 cases were, more or
less, evenly distributed between treatment groups, it is
unlikely that this one centre had any undue influence.
The cases from the only other practice to recruit more
than one case were randomly assigned to the same treat-
ment group (e.g. test treatment) group. Although not
ideal, the effect of this small ‘cluster’ is not likely to havehad a major bearing on outcome. A third limitation was
the fact that the study was short term and, arguably, a
longer period of therapy would have helped to determine
whether the treatment advantage identified was main-
tained, if the relative lack of efficacy of the control treat-
ment could ultimately have been overcome by further
dose increases, and if delayed side effects of the therap-
ies developed. That said, initial response (e.g. the first
2-3 months) has been shown to be critical in predicting
long-term response [3]. Longer term and larger scale
trials are now recommended, to enable a more complete
understanding of the treatment advantage that enteric
coating provides.
A further study limitation was the fact that diet was
not standardised amongst study dogs, and details of
exact diets were not recorded as part of the study. Diet-
ary management is recommended as adjunctive therapy
in canine EPI, and the most important consideration
appears to be in fat content with fat restriction recom-
mended in some [10,11], but not all [12,13], studies. Fur-
ther, prospective studies have not demonstrated a clear
benefit of any specific diet in the treatment of canine
EPI [13-15]. In fact, different diet types (i.e. low fat, nor-
mal fat high fibre) appeared to suit different dogs,
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response. Therefore, whilst a single diet type for all dogs
might have allowed greater uniformity to expected
responses, it might actually have confounded the re-
sponse to therapy, with either a favourable or unfavour-
able response being the result of the dietary change
rather than the enzyme treatments. As a result, clients
were advised not to alter diet in anyway, and this would
have the benefit that any improvements would then be
the result of the enzyme replacement therapy rather
than the diet change. Another reason for not switching
diets is the fact that many veterinary practices in the UK
stock only a limited diet range (e.g. from a single manu-
facturer), and it would have been difficult to choose a
single diet that was acceptable to all participants. Fur-
ther, altering to a purpose-formulated diet would have
cost implications, and might have deterred clients from
agreeing to participate. Moreover, there may have been
palatability issues with a dietary change, with not all
dogs accepting transition to a different diet. Nonetheless,
the issue over non-standardised diet is a potential limita-
tion, and future studies regarding EPI therapy should
consider standardising the diet between treatment
groups.
The demographic of cases recruited was similar to that
of previous studies [16], and the majority of cases were
seen and managed by primary care veterinarians. This
suggests that the results are likely to be relevant and can
be generalised to cases of EPI seen in general practice.
One limit to generalisability, however, is that, whilst the
test treatment was identical to a commercially available
product, the control treatment was not. Therefore, the
results are relevant to this particular commercial product
and also shed light on the principle of using an enteric
coating to reduce enzyme degradation, but caution
should be exercised when extrapolating to other enzyme
preparations. Further, demonstrating that enteric coating
is superior in this context does not necessarily prove that
the commercial product on which it is based is superior
to other commercially available uncoated preparations e.
g. uncoated enzyme powder. Although comparing two
commercially-available products would arguably have
been more relevant for decision-making in clinical prac-
tice, this approach would have been more difficult (if not
impossible) to blind as thoroughly as was achieved using
the test and control treatments in the current study. A
further challenge would have been ensuring that such
treatments were dosed at a comparative level. Therefore,
whilst caution should rightly be exercised when extrapo-
lating the results to all enzyme preparations, the findings
are still applicable for guiding therapeutic recommenda-
tions in this field.
Hypocobalaminaemia can be seen in the majority of
dogs with EPI, and negatively impacts upon long-termsurvival [3]. More concerningly, despite the laboratory
evidence of a deficiency, most EPI dogs with concurrent
hypocobalaminaemia do not receive adequate cobalamin
supplementation [3]. To reduce the possibility of hypo-
cobalaminaemia being a confounding factor in this trial,
one approach would have been to test cobalamin con-
centrations at each visit, and administer cobalamin injec-
tions to dogs that were deficient. However, this would
have been costly and might have dissuaded clients and
veterinary practices from participating. Since, parenteral
cobalamin injections are inexpensive and safe, we
decided on the alternative strategy of treating all dogs
with weekly cobalamin injections irrespective of their
circulating cobalamin concentration. The finding that
pre-treatment cobalamin status was negatively associated
with treatment response should be interpreted cautiously
because it was not a primary aim of the study, and was
identified using post-hoc ancillary analyses. Further,
since cobalamin status did not differ between groups,
and the effect was independent of treatment effect, it
was unlikely to have had an effect on the other study
findings. Nonetheless, the finding is consistent with the
previous regarding concurrent hypocobalaminaemia in
EPI patients. Further work is, therefore, required to as-
certain the pathological consequences of hypocobalami-
naemia in canine EPI, and the impact it may have in
response to current therapeutic regimes.
Conclusions
This study is the first RCT assessing efficacy of enzyme
replacement therapy in canine EPI. The study was rigor-
ously blinded, conducted under GCP guidelines and
reported according to recommended methods. Based
upon the primary outcome measure, dogs receiving an
enteric-coated pancreatic enzyme supplement responded
better to therapy than those given an otherwise identical
uncoated product. Therefore, enteric coating appears to
convey a therapeutic advantage for such products, al-
though caution should be exercised when extrapolating
these findings to other preparations of pancreatic
extract.
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